Abbreviations: FTDP-17 ϭ frontotemporal dementia with parkinsonism; PPND ϭ pallido-ponto-nigral degeneration; PSP ϭ progressive supranuclear palsy Stanford and colleagues add a new kindred to the literature in the S305S kindred they studied (Stanford et al., 2000) , and we have identified a second family with the S305S on parkinsonism linked to chromosome 17 (Stanford et al., 2000) . They identified a novel silent mutation (S305S) in mutation (Dickson et al., 2000) in which the presenting features are behavioural changes and frontal lobe dementia, exon 10 of the tau gene and suggest that this mutation causes progressive supranuclear palsy (PSP) pathology. We believe but not parkinsonism. The pathology associated with the S305S mutation appears that this kindred should be considered to have frontotemporal dementia with parkinsonism (FTDP-17) rather than PSP. similar to that of the N279K mutation. Both mutations result in neuronal loss in the substantia nigra, cortical neuronal loss The S305S mutation leads to an increase in the splicing of exon 10 and excessive production of tau isoforms with ballooned neurones and tau-positive neuronal and glial inclusions in cortical and subcortical structures. Tufted containing four microtubule-binding repeats. A similar pathogenetic mechanism is observed in pallido-ponto-nigral astrocytes, a feature seen in the case reported by Stanford and colleagues (Stanford et al., 2000) , are not a feature in degeneration (PPND), which is caused by an N279K mutation in the tau gene. We have studied a kindred with PPND for PPND (Reed et al., 1998), and are also not a prominent feature in our patient with the S305S mutation. In that patient, the last 14 years (Wszolek et al., 1992). Of the 311 family members, 39 individuals were affected by the disease; detailed double immunolabelling studies with tau and glial fibrillary acidic protein indicated that almost all the glial inclusions clinical information is available on 30. On the basis of our knowledge of PPND, we do not find it surprising that patients were in oligodendroglia. Tau-positive astrocytic inclusions were rare, and those that were present did not resemble with the S305S mutation exhibit parkinsonian signs and supranuclear gaze palsy. The majority of the patients with the tufted astrocytes typical of PSP. Because Stanford and colleagues did not do double immunostaining, it is difficult PPND also had parkinsonism as a predominant clinical feature, and 20 out of 30 (67%) had a cardinal feature of to know what proportion of the tau-positive glia in their patient with S305S were astrocytic. parkinsonism as the initial neurological finding (Table 1) . Eye movement abnormalities, including supranuclear gaze On the basis of the available information, it is difficult to know whether the pathology in the S305S kindred described palsies, occur in the second and third stages of the disease (Wszolek et al., 1992; Wszolek and Pfeiffer, 1993).
. D ϭ dementia; F ϭ female; M ϭ male; P ϭ parkinsonism; PC ϭ personality change. *Examined by Z.K.W.
bundles contained twisted filaments, which we also found in of PSP is still poorly understood, there is no evidence that PSP is associated with increased expression of 4-repeat tau. our patient with the S305S mutation. This twisted ribbon structure is not consistent with the filamentous inclusions
The report by Stanford et al. (2000) reflects a tendency to seen in PSP, which are straight filaments. assign a relatively common diagnostic term-in this case Thus, although the clinical and pathological signs found PSP-to a rare disorder with which it shares only a few in the kindred with the S305S mutation resemble PSP in clinical and pathological features, but which may have a very some respects, we believe that the differences outweigh the different aetiology. For the sake of clarity, defined research similarities and that it is misleading to imply that the S305S criteria should be followed to enable a more consistent mutation may be a genetic cause of PSP. Our contention is definition of such conditions. that this kindred has a form of FTDP-17, not PSP. FTDP-17 kindreds have various clinical presentations (Reed et al., 2001) including parkinsonism, supranuclear gaze palsy, Abbreviations: FTDP-17 ϭ frontotemporal dementia with parkinsonism linked to chromosome 17; PSP ϭ progressive supranuclear palsy
In their letter to the editor above, Wszolek and colleagues extended haplotype within the tau gene in individuals with the disorder (Conrad et al., 1997; Bennett et al., 1998 ; consider that an individual with a clinicopathological description of progressive supranuclear palsy (PSP) from a Higgins et al., 1998 Higgins et al., , 2000 Oliva et al., 1998; Baker et al., 1999; Morris et al., 1999 . Rojo and colleagues pedigree with an S305S tau gene mutation (Stanford et al., 2000) , may have frontotemporal dementia with parkinsonism highlighted the familial nature of PSP and the clinical heterogeneity observed within such kindreds (Rojo et al., rather than PSP (Wszolek et al., 2001 ). An international consensus conference 1999). It was therefore not unexpected that our pedigree with a S305S tau gene mutation has similar heterogeneity (Stanford concluded that, although highly variable, numerous pedigrees with frontotemporal dementia, behavioural disturbances and et al., 2000) . PSP clinical features and PSP-like pathology have been observed in other pedigrees with tau gene mutations parkinsonism linked to chromosome 17 were best defined as having FTDP-17 (Foster et al., 1997) . PSP-like pathology is (Reed et al., 1997; see Table 3 in Stanford et al., 2000) . The pathological criteria for PSP are a high density of seen in a number of FTDP-17 pedigrees including the pedigree studied by Wszolek and colleagues (Wszolek et al., neurofibrillary tangles and neuropil threads in the basal ganglia and brainstem. In our subject, more than six tangles 2001) (see Table 3 in Stanford et al., 2000) . Since we document an individual with a clinicopathological diagnosis were observed per high power field in these regions (see Table 2 , Stanford et al., 2000) , while cortical tangles were of PSP, we believe that the descriptor FTDP-17, for our S305S pedigree, may be misleading. A more appropriate less frequent. Recent studies have found that tufted astrocytes in the motor cortex and striatum distinguish PSP from descriptor may be 'familial tauopathy' (Spillantini et al., 1998a; Lee and Trojanowski, 1999; van Slegtenhorst et al., corticobasal degeneration (Bergeron et al., 1997; Komori et al., 1998; Matsusaka et al., 1998; Dickson, 1999) . As can 2000) as this would encompass both frontotemporal dementia and PSP.
be seen from our quantitative pathology, tufted astrocytes were numerous in the motor cortex (more than two per highMutations that cause PSP have been suspected from the association of a polymorphic dinucleotide marker and an power field; see Table 2 in Stanford et al., 2000) . Although we did not perform double labelling for glial fibrillary acidic considered as a whole, tau gene disorders should more accurately be referred to as familial tauopathies. protein, tufted astrocytes are easily distinguished from other glial types, as evidenced in other studies (Bergeron et al., 1997; Komori et al., 1998; Matsusaka et al., 1998) Stanford et al., 2000) . This lack of considerable progressive supranuclear palsy. Neurology 1998; 51: 982-5. atrophy is consistent with a diagnosis of PSP. Ballooned neurones were only found in the frontal regions sampled (see Bergeron C, Pollanen MS, Weyer L, Lang AE. Cortical degeneration Table 2 in Stanford et al., 2000) . As demonstrated by others, in progressive supranuclear palsy. A comparison with cortical-basal ganglionic degeneration. J Neuropathol Exp Neurol 1997; 56: the use of neurofilament immunohistochemistry greatly 726-34. facilitates the detection of such neurones in most PSP cases (Mackenzie and Hudson, 1995; Mori et al., 1996) . The and Litvan et al. (1996) . (Wszolek et al., 2001 ). However, many other studies disagree 1999; 58: 667-77. with this and have shown that the filaments in PSP consist ( Sergeant et al., 1999) . This is consistent with our exon trapping experiments which showed increased splicing of Flament S, Delacourte A, Verny M, Hauw JJ, Javoy-Agid F. exon 10 (Stanford et al., 2000) .
Abnormal Tau proteins in progressive supranuclear palsy.
Single mutations within the tau gene can give rise to a Similarities and differences with the neurofibrillary degeneration of wide spectrum of clinical presentations and neuropathology, the Alzheimer type. Acta Neuropathol (Berl) 1991; 81: 591-6. both within (Bugiani et al., 1999; Stanford et al., 2000) and and possibly even Pick's disease (Spillantini et al., 1998b;  Richardson-Olszewski syndrome (progressive supranuclear palsy). Murrell et al., 1999; Rizzini et al., 2000) . Wszolek and [Review] . Neurology 1994; 44: 2015-19. colleagues suggest that all kindreds, including our S305S Higgins JJ, Litvan I, Pho LT, Li W, Nee LE. Progressive supranuclear pedigree with a PSP individual, should be broadly grouped gaze palsy is in linkage disequilibrium with the τ and not the under the highly descriptive nomenclature of FTDP-17 α-synuclein gene. Neurology 1998; 50: 270-3. (Wszolek et al., 2001) . However, in view of the expanding knowledge of tau gene mutations, we consider that this seen in disease phenotypes. Therefore, if they are to be
